Although wet AMD can be treated with FDA-approved intravitreal anti-vascular endothelial growth factor (VEGF) drug injections, such as Lucentis and Eylea, these treatments are not universally responsive, are invasive, and are associated with potential side effects [5,6,7,8]. This evidence concerns the gene VEGFA and wet macular degeneration.